Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial.

Goujard C, Emilie D, Roussillon C, Godot V, Rouzioux C, Venet A, Colin C, Pialoux G, Girard PM, Boilet V, Chaix ML, Galanaud P, Chene G; ANRS-112 INTERPRIM Study Group..

AIDS. 2012 Sep 24;26(15):1895-905.

PMID:
22842994
2.

Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.

Goujard C, Marcellin F, Hendel-Chavez H, Burgard M, Meiffrédy V, Venet A, Rouzioux C, Taoufik Y, El Habib R, Beumont-Mauviel M, Aboulker JP, Lévy Y, Delfraissy JF; PRIMOVAC-ANRS 095 Study Group..

AIDS Res Hum Retroviruses. 2007 Sep;23(9):1105-13.

PMID:
17919105
3.

Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.

Sued O, Ambrosioni J, Nicolás D, Manzardo C, Agüero F, Claramonte X, Plana M, Tuset M, Pumarola T, Gallart T, Gatell JM, Miró JM.

PLoS One. 2015 Jul 17;10(7):e0131651. doi: 10.1371/journal.pone.0131651.

4.

HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M; ANRS CO6 PRIMO Study Group..

Antivir Ther. 2012;17(6):1001-9. doi: 10.3851/IMP2273.

PMID:
22865544
5.

Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions.

Bunupuradah T, Duong T, Compagnucci A, McMaster P, Bernardi S, Kanjanavanit S, Rampon O, Faye A, Saïdi Y, Riault Y, De Rossi A, Klein N, Ananworanich J, Gibb D; PENTA 11 Extension Study Group..

AIDS. 2013 Feb 20;27(4):579-89. doi: 10.1097/QAD.0b013e32835c1181.

PMID:
23135172
6.

The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.

Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, Abad-Fernandez M, Dronda F, Perez-Elias MJ, Zamora J, Muñoz E, Muñoz-Fernandez MA, Moreno S.

AIDS. 2012 Sep 24;26(15):1885-94.

PMID:
22992577
7.

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Oxenius A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, García F, Hirschel B, McLean A, Phillips RE.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52.

8.

CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.

Yazdanpanah Y, Wolf LL, Anglaret X, Gabillard D, Walensky RP, Moh R, Danel C, Sloan CE, Losina E, Freedberg KA; CEPAC-International Investigators..

Antivir Ther. 2010;15(3):351-61. doi: 10.3851/IMP1542.

9.

Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.

Pai NP, Lawrence J, Reingold AL, Tulsky JP.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006148. Review.

PMID:
16856117
10.

Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.

Massanella M, Tural C, Papagno L, Garcia E, Jou A, Bofill M, Autran B, Clotet B, Blanco J.

Antivir Ther. 2010;15(3):333-42. doi: 10.3851/IMP1531.

PMID:
20516553
11.
12.

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.

García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM.

AIDS. 2001 Jun 15;15(9):F29-40.

PMID:
11416735
13.

Immunological and virological effects of structured treatment interruptions following exposure to hydroxyurea plus didanosine.

Benito JM, López M, Ballesteros C, Lozano S, Capa L, Barreiro P, Sempere J, Gonzalez-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2006 Aug;22(8):734-43.

PMID:
16910828
14.

Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.

Palacios GC, Sanchez LM, Briones E, Ramirez TJ, Castillo H, Rivera LG, Vazquez CA, Rodriguez-Padilla C, Holodniy M.

Int J Infect Dis. 2010 Jan;14(1):e34-40. doi: 10.1016/j.ijid.2009.03.003.

15.

Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.

Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D; STOPAR study team..

Antivir Ther. 2013;18(1):125-30. doi: 10.3851/IMP2249.

PMID:
22805174
17.

Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.

Milazzo L, Foschi A, Mazzali C, Viola A, Ridolfo A, Galli M, Antinori S.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):989-93. doi: 10.1089/AID.2011.0323.

18.

The effect of continuous versus pericycle antiretroviral therapy on IL-2 responsiveness.

Healey LM, Hahn BK, Rehm CA, Adelsberger J, Qin J, Follmann DA, Tavel J, Kovacs JA, Sereti I, Davey RT Jr.

J Interferon Cytokine Res. 2008 Jul;28(7):455-62. doi: 10.1089/jir.2007.0120.

19.

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.

Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, Negredo E, Sirera G, Tural C, Clotet B.

AIDS. 2000 Mar 10;14(4):397-403.

PMID:
10770542
20.

Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.

Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM.

J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):791-9.

PMID:
15213562
Items per page

Supplemental Content

Support Center